| Page 5 | Cafepharma

You are here

Primary tabs

SBIR Awards $2.3 Million Grant to Agilvax to Advance Immunotherapy for Triple Negative Breast Cancer

Post date: August 7, 2018 - 9:59am

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

Post date: July 13, 2018 - 9:28am

Advaxis Shares Jump After FDA Lifts Clinical Hold on Phase 1/2 Study

Post date: July 13, 2018 - 9:05am

FDA Releases Six New Draft Guidances on Gene Therapy

Post date: July 12, 2018 - 9:51am

Landos Biopharma Initiates Ph I Trial of First-in-class Oral Treatment for IBD

Post date: July 12, 2018 - 9:17am

Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors

Post date: July 12, 2018 - 8:58am

Opdivo Gains New Approval in Combination with Yervoy

Post date: July 11, 2018 - 10:11am

Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant

Post date: July 11, 2018 - 9:56am

Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer

Post date: July 11, 2018 - 9:37am

FTC Clears Takeda's Acquisition of Shire

Post date: July 10, 2018 - 9:49am

Pages